In a statement, the Jamaica Anti-Doping Commission said "some procedures" were faulty, only specifying that "no partial sample kits were used" in the collection process when Campbell-Brown's urine was obtained at a national meet in May.
Carey Brown, who was appointed as executive director of JADCO in October, a couple of weeks before all 12 board members of the commission stepped down amid questions about drug testing on the island, added there was no permission from the World Anti-Doping Agency to deviate from the standard rules.
He said the restructured agency has been busily upgrading its operational procedures in recent months "to remove any weaknesses in the system."
In a report released Tuesday, the Court of Arbitration for Sport said it cleared Campbell-Brown of doping because of "deplorable" flaws in the test collection procedures in Jamaica and possible "environmental contamination" of her urine sample.
The three-time Olympic gold medalist tested positive for the diuretic HCT at the May meet in Jamaica. She denied intentionally taking any prohibited substance and CAS upheld her appeal against a two-year doping ban.
She was initially suspended provisionally by the International Association of Athletics Federations. In September, a Jamaican disciplinary panel gave her a reprimand, but the IAAF contested the finding and ordered the Jamaican federation earlier this year to impose a two-year suspension.
A three-man CAS arbitration panel found that the sprinter established a "credible" possibility that her positive test resulted from Jamaica's failure to comply with the international standards for partial sample testing.
Peter Sever, head of the clinical pharmacology department at Imperial College in London, testified that the most likely explanation for her positive test was contamination of her sample through sweat or water containing HCT, a common medication for high blood pressure.
No comments:
Post a Comment